As of 2024-12-15, the Intrinsic Value of TG Therapeutics Inc (TGTX) is
0.76 USD. This TGTX valuation is based on the model Discounted Cash Flows (Growth Exit 10Y).
With the current market price of 32.02 USD, the upside of TG Therapeutics Inc is
-97.60%.
The range of the Intrinsic Value is 0.10 - 2.92 USD
TGTX Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(5.04) - (2.17) |
(2.84) |
-108.9% |
| DCF (Growth 10y) |
0.10 - 2.92 |
0.76 |
-97.6% |
| DCF (EBITDA 5y) |
10.27 - 14.25 |
11.71 |
-63.4% |
| DCF (EBITDA 10y) |
9.01 - 14.05 |
10.91 |
-65.9% |
| Fair Value |
-1.17 - -1.17 |
-1.17 |
-103.66% |
| P/E |
(1.60) - 3.20 |
(0.06) |
-100.2% |
| EV/EBITDA |
0.26 - 10.32 |
4.08 |
-87.3% |
| EPV |
(9.08) - (12.16) |
(10.62) |
-133.2% |
| DDM - Stable |
(1.05) - (4.43) |
(2.74) |
-108.5% |
| DDM - Multi |
0.95 - 3.11 |
1.45 |
-95.5% |
TGTX Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
4,984.55 |
| Beta |
1.29 |
| Outstanding shares (mil) |
155.67 |
| Enterprise Value (mil) |
5,032.89 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.02% |
| Cost of Debt |
17.81% |
| WACC |
8.12% |